296 related articles for article (PubMed ID: 11103058)
1. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Takeshita A; Sugiyama S; Satoh H; Terada H; Ohno R
Ann Intern Med; 2000 Dec; 133(11):881-5. PubMed ID: 11103058
[TBL] [Abstract][Full Text] [Related]
2. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Barbey JT; Soignet S
Ann Intern Med; 2001 Nov; 135(9):842-3. PubMed ID: 11694116
[No Abstract] [Full Text] [Related]
3. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
4. Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
Ducas RA; Seftel MD; Ducas J; Seifer C
J R Coll Physicians Edinb; 2011 Jun; 41(2):117-8. PubMed ID: 21677914
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring.
Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Sahara N; Takeshita A; Satoh H; Terada H; Ohno R
Leukemia; 2002 Apr; 16(4):617-22. PubMed ID: 11960341
[TBL] [Abstract][Full Text] [Related]
6. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.
Unnikrishnan D; Dutcher JP; Varshneya N; Lucariello R; Api M; Garl S; Wiernik PH; Chiaramida S
Blood; 2001 Mar; 97(5):1514-6. PubMed ID: 11222403
[TBL] [Abstract][Full Text] [Related]
7. Ventricular repolarization dynamics in arsenic trioxide treatment of acute promyelocytic leukemia.
Sun Y; Wang L; Que Y; Zhu H; Yang X; Li D
Int J Cardiol; 2020 May; 306():163-167. PubMed ID: 31761398
[TBL] [Abstract][Full Text] [Related]
8. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia.
Huang SY; Chang CS; Tang JL; Tien HF; Kuo TL; Huang SF; Yao YT; Chou WC; Chung CY; Wang CH; Shen MC; Chen YC
Br J Haematol; 1998 Dec; 103(4):1092-5. PubMed ID: 9886325
[TBL] [Abstract][Full Text] [Related]
9. Arrhythmogenic effects of arsenic trioxide in patients with acute promyelocytic leukemia and an electrophysiological study in isolated guinea pig papillary muscles.
Yamazaki K; Terada H; Satoh H; Naito K; Takeshita A; Uehara A; Katoh H; Ohnishi K; Hayashi H
Circ J; 2006 Nov; 70(11):1407-14. PubMed ID: 17062962
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.
Shigeno K; Naito K; Sahara N; Kobayashi M; Nakamura S; Fujisawa S; Shinjo K; Takeshita A; Ohno R; Ohnishi K
Int J Hematol; 2005 Oct; 82(3):224-9. PubMed ID: 16207595
[TBL] [Abstract][Full Text] [Related]
11. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.
Westervelt P; Brown RA; Adkins DR; Khoury H; Curtin P; Hurd D; Luger SM; Ma MK; Ley TJ; DiPersio JF
Blood; 2001 Jul; 98(2):266-71. PubMed ID: 11435292
[TBL] [Abstract][Full Text] [Related]
12. Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia.
Cashin R; Burry L; Peckham K; Reynolds S; Seki JT
Am J Health Syst Pharm; 2008 May; 65(10):941-6. PubMed ID: 18463343
[TBL] [Abstract][Full Text] [Related]
13. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
Fox E; Razzouk BI; Widemann BC; Xiao S; O'Brien M; Goodspeed W; Reaman GH; Blaney SM; Murgo AJ; Balis FM; Adamson PC
Blood; 2008 Jan; 111(2):566-73. PubMed ID: 17959855
[TBL] [Abstract][Full Text] [Related]
15. QT prolongation: a case of arsenical pericardial and pleural effusion.
Vizzardi E; Zanini G; Antonioli E; D'Aloia A; Raddino R; Cas LD
Cardiovasc Toxicol; 2008 Mar; 8(1):41-4. PubMed ID: 18084726
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
Prescrire Int; 2004 Aug; 13(72):135-7. PubMed ID: 15532137
[TBL] [Abstract][Full Text] [Related]
17. Risk/benefit profile of arsenic trioxide.
Rust DM; Soignet SL
Oncologist; 2001; 6 Suppl 2():29-32. PubMed ID: 11331438
[TBL] [Abstract][Full Text] [Related]
18. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient.
Huang CH; Chen WJ; Wu CC; Chen YC; Lee YT
Pacing Clin Electrophysiol; 1999 Jun; 22(6 Pt 1):965-7. PubMed ID: 10392399
[TBL] [Abstract][Full Text] [Related]
19. Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction.
Roberts TF; Sprague K; Schenkein D; Miller KB; Relias V
Blood; 2000 Dec; 96(12):4000-1. PubMed ID: 11186272
[No Abstract] [Full Text] [Related]
20. Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy.
Naito K; Kobayashi M; Sahara N; Shigeno K; Nakamura S; Shinjo K; Tobita T; Takeshita A; Ohno R; Ohnishi K
Int J Hematol; 2006 May; 83(4):318-23. PubMed ID: 16757431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]